ID: ALA192835

Max Phase: Preclinical

Molecular Formula: C23H25N5O3

Molecular Weight: 419.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(C#CCCCCC(=O)O)cc1Cc1cnc2nc(N)nc(N)c2c1C

Standard InChI:  InChI=1S/C23H25N5O3/c1-14-17(13-26-22-20(14)21(24)27-23(25)28-22)12-16-11-15(9-10-18(16)31-2)7-5-3-4-6-8-19(29)30/h9-11,13H,3-4,6,8,12H2,1-2H3,(H,29,30)(H4,24,25,26,27,28)

Standard InChI Key:  KGIGVDGEORZUCT-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 419.49

Molecular Weight (Monoisotopic): 419.1957

AlogP: 3.09

#Rotatable Bonds: 7

Polar Surface Area: 137.24

Molecular Species: ACID

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 4.08

CX Basic pKa: 2.64

CX LogP: 3.84

CX LogD: 0.92

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.39

Np Likeness Score: 0.04

References

1. Chan DC, Fu H, Forsch RA, Queener SF, Rosowsky A..  (2005)  Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.,  48  (13): [PMID:15974594] [10.1021/jm0581718]

Source

Source(1):

• Scientific Literature